Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hilo 32 Plus is a hyaluronic acid-based skin booster developed by Glamderma and marketed as an analog to the well-known Profhilo treatment. It is a finished aesthetic product designed for mesotherapy, administered via injection into the epidermal and dermal layers of the skin. The formulation is intended for cosmetic indications such as skin rejuvenation, deep hydration, and volume restoration, providing a lifting effect and enhancing skin elasticity. It functions by delivering high concentrations of hyaluronic acid to the skin tissue, which promotes tissue remodeling and stimulates the production of endogenous collagen and elastin. Unlike investigational pharmaceutical drugs, Hilo 32 Plus is commercially available as a finished aesthetic product primarily distributed through specialized medical e-commerce platforms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hilo 32 Plus.